Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Colin Garner

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Bioanalysis|November 19, 2010
Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK dataR Colin Garner
Drug Discovery Today|April 6, 2005
Less is more: the human microdosing conceptR Colin Garner
Nature Reviews. Drug Discovery|March 4, 2003
Big physics, small doses: the use of AMS and PET in human microdosing of development drugsGraham Lappin, R Colin Garner
Analytical and Bioanalytical Chemistry|November 19, 2003
Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometryGraham Lappin, R Colin Garner
British Journal of Clinical Pharmacology|March 18, 2006
The phase 0 microdosing conceptR Colin Garner, Graham Lappin
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
The use of accelerator mass spectrometry to obtain early human ADME/PK dataGraham Lappin, R Colin Garner
Expert Opinion on Drug Metabolism & Toxicology|December 2, 2008
The utility of microdosing over the past 5 yearsGraham Lappin, R Colin Garner
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
The use of isotopes in the determination of absolute bioavailability of drugs in humansGraham Lappin, Malcolm Rowland, R Colin Garner
Journal of Clinical Pharmacology|September 25, 2009
Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjectsXiao-Jian Zhou, R Colin Garner, Sheila Nicholson, et al.
Carcinogenesis|September 2, 2003
Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytesJames R Bacon, Gary Williamson, R Colin Garner, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Bioanalysis|November 19, 2010
Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK dataR Colin Garner
Drug Discovery Today|April 6, 2005
Less is more: the human microdosing conceptR Colin Garner
Nature Reviews. Drug Discovery|March 4, 2003
Big physics, small doses: the use of AMS and PET in human microdosing of development drugsGraham Lappin, R Colin Garner
Analytical and Bioanalytical Chemistry|November 19, 2003
Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometryGraham Lappin, R Colin Garner
British Journal of Clinical Pharmacology|March 18, 2006
The phase 0 microdosing conceptR Colin Garner, Graham Lappin
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
The use of accelerator mass spectrometry to obtain early human ADME/PK dataGraham Lappin, R Colin Garner
Expert Opinion on Drug Metabolism & Toxicology|December 2, 2008
The utility of microdosing over the past 5 yearsGraham Lappin, R Colin Garner
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
The use of isotopes in the determination of absolute bioavailability of drugs in humansGraham Lappin, Malcolm Rowland, R Colin Garner
Journal of Clinical Pharmacology|September 25, 2009
Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjectsXiao-Jian Zhou, R Colin Garner, Sheila Nicholson, et al.
Carcinogenesis|September 2, 2003
Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytesJames R Bacon, Gary Williamson, R Colin Garner, et al.
Pageof 2